Overall Survival of Nonmetastasized NSCLC Patients Treated With Add-On Viscum album L: A Multicenter Real-World Study.
Anja ThronickeBurkhard MatthesPhilipp von TrottFriedemann SchadChristian GrahPublished in: Integrative cancer therapies (2021)
Our findings support the importance of surgery as the most effective intervention in nonmetastasized NSCLC patients. Add-on VA therapy shows here no additional effect in resected patients. However, a small subgroup analysis suggests a possible role of add-on VA for nonresected subgroups. Our results complement existing knowledge on the clinical impact of add-on VA therapy in NSCLC patients and may serve as hypothesis-generating data for further examinations in this cohort. Further research could be directed towards the role of combined therapy for nonresected early-stage NSCLC.
Keyphrases
- end stage renal disease
- small cell lung cancer
- early stage
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- healthcare
- randomized controlled trial
- peritoneal dialysis
- lymph node
- minimally invasive
- machine learning
- stem cells
- coronary artery disease
- radiation therapy
- atrial fibrillation
- open label
- sentinel lymph node
- patient reported